Last reviewed · How we verify
SOGROYA (SOMAPACITAN-BECO)
SOGROYA (generic name: SOMAPACITAN-BECO) is a drug developed by NOVO NORDISK INC. It is currently FDA-approved for Growth failure due to inadequate GH secretion, Short stature SGA without catch-up growth, Growth failure associated with Noonan syndrome.
Sogroya is a small molecule growth hormone receptor agonist used to treat conditions such as Adult Growth Hormone Deficiency, Gastroparesis, and Growth Hormone Deficiency in Children. It is administered as Somapacitan, which is a form of growth hormone.
At a glance
| Generic name | SOMAPACITAN-BECO |
|---|---|
| Sponsor | NOVO NORDISK INC |
| Target | Growth hormone receptor |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Growth failure due to inadequate GH secretion
- Short stature SGA without catch-up growth
- Growth failure associated with Noonan syndrome
- Idiopathic Short Stature
- Replacement of endogenous GH in GHD adults
Common side effects
- Nasopharyngitis
- Respiratory Tract Infection
- Pyrexia
- Cough
- Ear Infection
- Diarrhea
- Vomiting
- Bronchitis
- Headache
- Pain in extremity
- Injection site reaction
- Nausea/vomiting
Serious adverse events
- Adenoidal and tonsillar hypertrophy
Drug interactions
- Cortisone acetate, Prednisone
- Cytochrome P450-metabolized drugs
- Oral Estrogen
- Insulin and/or Other Hypoglycemic Agents
Key clinical trials
- Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® A Multi-centre, Prospective, Open Label, Single-arm, Observational, Non-interventional Post-marketing Stud (N/A)
- A Multi-centre, Prospective, Open Label, Single-arm, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Clinical Parameters of Sogroya® Treatment in Children With Short St (N/A)
- Low-dose Growth Hormone for the Treatment of Gastroparesis (EARLY/Phase 1)
- A Multi-national, Multi-centre, Prospective, Single-arm, Observational, Non-interventional Post-authorisation Safety Study to Investigate Long-term Safety of Sogroya® (Somapacitan) in Adults With Grow (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOGROYA CI brief — competitive landscape report
- SOGROYA updates RSS · CI watch RSS
- NOVO NORDISK INC portfolio CI
Frequently asked questions about SOGROYA
What is SOGROYA?
What is SOGROYA used for?
Who makes SOGROYA?
What is the generic name of SOGROYA?
What development phase is SOGROYA in?
What are the side effects of SOGROYA?
What does SOGROYA target?
Related
- Target: All drugs targeting Growth hormone receptor
- Manufacturer: NOVO NORDISK INC — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Growth failure due to inadequate GH secretion
- Indication: Drugs for Short stature SGA without catch-up growth
- Indication: Drugs for Growth failure associated with Noonan syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing